One of the major limitations of chemotherapy in cancer treatment is the side effects of anti-cancer drugs, which are due to their toxicity, their non-selective distribution and their action on cancer and normal dividing cells. The ultimate goal of this study is to develop a novel delivery system for the potent and cytotoxic compound CCI-001 to protect it from degradation, help its transport throughout the body, improve its therapeutic efficacy and reduce its harmful side effects. Albumin, one of the most abundant proteins in blood plasma, has shown to be non-toxic, non-immunogenic, biocompatible and biodegradable. Furthermore, it strongly interacts with both hydrophilic and hydrophobic compounds.